- Home
- Publications
- Publication Search
- Publication Details
Title
Vaccine Therapies for Cancer: Then and Now
Authors
Keywords
-
Journal
Targeted Oncology
Volume 16, Issue 2, Pages 121-152
Publisher
Springer Science and Business Media LLC
Online
2021-01-30
DOI
10.1007/s11523-020-00788-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens
- (2020) Geoffrey M. Lynn et al. NATURE BIOTECHNOLOGY
- Engineered Nanodelivery Systems to Improve DNA Vaccine Technologies
- (2020) Michael Lim et al. Pharmaceutics
- Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling
- (2020) Anthony C. Antonelli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Retrospective Observational Analysis of Overall Survival with Sipuleucel-T in Medicare Beneficiaries Treated for Advanced Prostate Cancer
- (2020) Rana R. McKay et al. ADVANCES IN THERAPY
- 1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of phase III ATALANTE-1 randomised trial
- (2020) G. Giaccone et al. ANNALS OF ONCOLOGY
- Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study
- (2019) Erika J Crosby et al. CLINICAL CANCER RESEARCH
- Turning the corner on therapeutic cancer vaccines
- (2019) Robert E. Hollingsworth et al. npj Vaccines
- Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
- (2019) Tanner M. Johanns et al. OncoImmunology
- A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8+ T-cell Responses, Impacting Tumor Challenge
- (2019) Elizabeth K. Duperret et al. Cancer Immunology Research
- Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors
- (2019) Patrick A. Ott et al. Cancer Discovery
- Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer
- (2019) James L. Gulley et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial
- (2019) Elizabeth A. Mittendorf et al. CLINICAL CANCER RESEARCH
- Pathogen molecular pattern receptor agonists: treating cancer by mimicking infection
- (2019) Mark Aleynick et al. CLINICAL CANCER RESEARCH
- 4Vaccination Of Cancer Patients With Dendritic Cells Electroporated with mRNA Encoding the Wilms' Tumor 1 Protein (WT1): Correlation Of Clinical Effect And Overall Survival With T-cell Response
- (2019) Z.N. Berneman et al. CYTOTHERAPY
- Cancer Vaccines
- (2019) Peter J. DeMaria et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.
- (2019) Gal Cafri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
- (2019) Alessandra Lopes et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination
- (2019) Linda Hammerich et al. NATURE MEDICINE
- Phase I/II pilot study of WT1 peptide‐pulsed dendritic cell vaccination combined with conventional chemotherapy in patients with head and neck cancer
- (2019) Masahiro Ogasawara et al. THERAPEUTIC APHERESIS AND DIALYSIS
- A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy
- (2019) Masahiro Katsuda et al. Trials
- The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
- (2019) Kalijn F. Bol et al. Journal for ImmunoTherapy of Cancer
- Finding Neo (antigens, that is)
- (2019) Johanna Olweus et al. BLOOD
- A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
- (2019) Luis Teixeira et al. CLINICAL CANCER RESEARCH
- Peptides as cancer vaccines
- (2019) Marta Calvo Tardón et al. CURRENT OPINION IN PHARMACOLOGY
- Neoantigen Dissimilarity to the Self-Proteome Predicts Immunogenicity and Response to Immune Checkpoint Blockade
- (2019) Lee P. Richman et al. Cell Systems
- Current challenges for cancer vaccine adjuvant development
- (2018) William S. Bowen et al. Expert Review of Vaccines
- Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.
- (2018) Harm Westdorp et al. JOURNAL OF CLINICAL ONCOLOGY
- Dendritic Cell–Based Cancer Vaccines
- (2018) Patricia M. Santos et al. JOURNAL OF IMMUNOLOGY
- MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2018) Brigitte Dreno et al. LANCET ONCOLOGY
- Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study
- (2018) Sumiyuki Nishida et al. Cancer Immunology Research
- Computational Strategies for Dissecting the High-Dimensional Complexity of Adaptive Immune Repertoires
- (2018) Enkelejda Miho et al. Frontiers in Immunology
- A randomized, multicenter phase 2 study of DSP-7888 dosing emulsion in combination with bevacizumab (Bev) versus Bev alone in patients with recurrent or progressive glioblastoma.
- (2018) John Frederick De Groot et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-term survival of pancreatic cancer patients treated with multimodal therapy combined with WT1-targeted dendritic cell vaccines
- (2018) Shuichi Hanada et al. Human Vaccines & Immunotherapeutics
- A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma
- (2018) Akihiro Tsuboi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Actively personalized vaccination trial for newly diagnosed glioblastoma
- (2018) Norbert Hilf et al. NATURE
- Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
- (2018) Derin B. Keskin et al. NATURE
- Deep learning enables de novo peptide sequencing from data-independent-acquisition mass spectrometry
- (2018) Ngoc Hieu Tran et al. NATURE METHODS
- Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer
- (2017) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- (2017) Michael Weller et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA
- (2017) Orin Bloch et al. NEURO-ONCOLOGY
- Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
- (2017) Abhishek D. Garg et al. TRENDS IN IMMUNOLOGY
- An Overview of Novel Adjuvants Designed for Improving Vaccine Efficacy
- (2017) Srinivasa Reddy Bonam et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Enhancing Immune Responses to Cancer Vaccines Using Multi-Site Injections
- (2017) Robert C. Mould et al. Scientific Reports
- Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial
- (2016) Lea Lowenfeld et al. CLINICAL CANCER RESEARCH
- The development and use of the E75 (HER2 369–377) peptide vaccine
- (2016) Guy T Clifton et al. Future Oncology
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Designer vaccine nanodiscs for personalized cancer immunotherapy
- (2016) Rui Kuai et al. NATURE MATERIALS
- The Human Vaccines Project: A roadmap for cancer vaccine development
- (2016) Pedro Romero et al. Science Translational Medicine
- Optimization of Peptide Vaccines to Induce Robust Antitumor CD4 T-cell Responses
- (2016) Takumi Kumai et al. Cancer Immunology Research
- Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer
- (2016) Jashodeep Datta et al. JAMA Oncology
- Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses
- (2015) P. Mitchell et al. ANNALS OF ONCOLOGY
- Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study
- (2015) Hiroki Yamaue et al. CANCER SCIENCE
- Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells
- (2015) G. Schreibelt et al. CLINICAL CANCER RESEARCH
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Therapeutic cancer vaccines
- (2015) Cornelis J.M. Melief et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor neoantigens: building a framework for personalized cancer immunotherapy
- (2015) Matthew M. Gubin et al. JOURNAL OF CLINICAL INVESTIGATION
- Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E4697)
- (2015) David H. Lawson et al. JOURNAL OF CLINICAL ONCOLOGY
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
- (2015) Cornelia L Trimble et al. LANCET
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- Cancer vaccines
- (2015) L. H. Butterfield BMJ-British Medical Journal
- Cancer vaccines
- (2015) L. H. Butterfield BMJ-British Medical Journal
- Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication
- (2015) O. A. Ali et al. Cancer Immunology Research
- Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma
- (2014) Ronald Levy et al. JOURNAL OF CLINICAL ONCOLOGY
- Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
- (2014) Gary Middleton et al. LANCET ONCOLOGY
- Antigen-specific vaccines for cancer treatment
- (2014) Maria Tagliamonte et al. Human Vaccines & Immunotherapeutics
- CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
- (2014) H.-J. Kim et al. Cancer Immunology Research
- Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients
- (2013) J. Tel et al. CANCER RESEARCH
- Activation of Dendritic Cells by the Novel Toll-Like Receptor 3 Agonist RGC100
- (2013) Kai Naumann et al. Clinical & Developmental Immunology
- Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
- (2013) Rodney A. Rosalia et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
- (2013) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study
- (2013) Paul Sabbatini et al. JOURNAL OF CLINICAL ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53
- (2013) Ruey-Shyang Soong et al. PLoS One
- Clinical evaluation of therapeutic cancer vaccines
- (2013) Chizuru Ogi et al. Human Vaccines & Immunotherapeutics
- BiVax: a peptide/poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses
- (2012) Hyun-Il Cho et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Clinical Evaluation of TRICOM Vector Therapeutic Cancer Vaccines
- (2012) Ravi A. Madan et al. SEMINARS IN ONCOLOGY
- Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
- (2011) Deborah A. Grosenbaugh et al. AMERICAN JOURNAL OF VETERINARY RESEARCH
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
- (2011) Stephen J. Schuster et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
- (2011) Jacalyn Rosenblatt et al. JOURNAL OF IMMUNOTHERAPY
- Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review
- (2011) Benqiang Rao et al. Journal of Translational Medicine
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Enhancing the potency of a whole-cell breast cancer vaccine in mice with an antibody-IL-2 immunocytokine that targets exposed phosphatidylserine
- (2011) Xianming Huang et al. VACCINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma
- (2009) Howard L. Kaufman et al. ANNALS OF SURGICAL ONCOLOGY
- EGFRvIII-Targeted Vaccination Therapy of Malignant Glioma
- (2009) Bryan D. Choi et al. BRAIN PATHOLOGY
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Long-lasting cross-presentation of tumor antigen in human DC
- (2009) Florence Faure et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
- (2009) Arnold Freedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation
- (2008) Martijn S. Bijker et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Allovectin-7 therapy in metastatic melanoma
- (2008) Agop Y Bedikian et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase III Comparison of Vitespen, an Autologous Tumor-Derived Heat Shock Protein gp96 Peptide Complex Vaccine, With Physician's Choice of Treatment for Stage IV Melanoma: The C-100-21 Study Group
- (2008) Alessandro Testori et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started